Medpace Holdings, Inc. (MEDP) Stock Price & Analysis

Medpace Holdings, Inc. (MEDP) closed at USD 653.96 on Thursday, October 22, 2026, down 1.29% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 662.48; the Oct 22, 2026 session ranged USD 645.3–684.52 on volume of 893,815 shares. Market capitalization is $18.25B, with a 52-week range of USD 373–684.52 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:49 UTC.

Also available as compact Markdown for AI agents: nexqual.com/MEDP.md

Key facts (MEDP)

• Last four reported quarters (through Sep 30, 2026): revenue $2.84B, net income $518M (18.2% margin), free cash flow $668M (SEC filings).
• Valuation: P/E 35.2x (avg 32.5x at the last 3 fiscal year-ends).
• 4 of 80 tracked superinvestors hold MEDP (13F, Q2 2026): 0 new, 1 added, 3 reduced, 0 unchanged.
• Analysts: Hold (mean 2.86 on a 1–5 scale) (14 analysts), mean target USD 637.31 (range 370–730).
• Total return with dividends: 1Y +9.6% vs S&P 500 +14.9%; 5Y +249.6% vs S&P 500 +80.3%.
• Next earnings: 2026-10-21, EPS estimate USD 4.87, revenue estimate $719M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MEDP)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (MEDP)

P/E 35.2x · P/S 6.4x · P/FCF 27.3x · P/B 31.2x · FCF yield 3.66% · Earnings yield 2.84% · Buyback yield (TTM) 1.61%

P/E at fiscal year-ends: Dec 2025 36.8x, Dec 2024 26.3x, Dec 2023 34.5x.

Superinvestors (SEC 13F-HR, Q2 2026) (MEDP)

4 of 80 tracked investors hold MEDP. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Analysts (MEDP)

Consensus Hold (mean 2.86 on a 1–5 scale), 14 analysts; mean target USD 637.31 (low 370, high 730).

Rating changes, last 120 days:

Total return (dividends reinvested) (MEDP)

MEDP revenue by product line (quarter ended Sep 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

Companies that name MEDP in their SEC reports

MEDP company outlook (results filed Oct 21, 2026)

• “The Company forecasts 2026 revenue in the range of $2.835 billion to $2.855 billion, representing growth of 12.0% to 12.8% over 2025 revenue of $2.530 billion.”
• “GAAP net income for full year 2026 is forecasted in the range of $514.0 million to $524.0 million.”
• “Additionally, full year 2026 EBITDA is expected in the range of $638.0 million to $652.0 million.”
• “Based on forecasted 2026 revenue of $2.835 billion to $2.855 billion and GAAP net income of $514.0 million to $524.0 million, diluted earnings per share (GAAP) is forecasted in the range of $17.97 to $18.32.”

Quoted word-for-word from the SEC 8-K results press release.

MEDP analyst estimates and revisions

MEDP options: expected move

30-day implied volatility 34.1% vs 32.3% realized over the last 30 trading days. Put/call ratio (volume) 1.44. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:49 UTC)

Technical Analysis (MEDP)

Nexqual's technical model rates MEDP "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:49 UTC.

Analyst Ratings (MEDP)

Wall Street analysts rate MEDP "Hold" based on 14 analysts, with a mean price target of USD 637.31 (range USD 370–730), per Nexqual as of October 23, 2026 at 09:49 UTC.

Earnings (MEDP)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:49 UTC.

Financials & Fundamentals (MEDP)

Source: Nexqual, October 23, 2026 at 09:49 UTC.

Financial Health Score (MEDP)

Nexqual rates Medpace Holdings, Inc.'s overall financial health "Strong" across five dimensions, as of October 23, 2026 at 09:49 UTC.

Ownership (MEDP)

Source: Nexqual, October 23, 2026 at 09:49 UTC.

Leadership (MEDP)

Medpace Holdings, Inc. is led by August James Troendle, CEO, President & Chairman, per Nexqual as of October 23, 2026 at 09:49 UTC.

Major Backers & Investors (MEDP)

Notable institutional backers of Medpace Holdings, Inc. include Price (T.Rowe) Associates Inc, AQR Capital Management, LLC, Invesco, according to Nexqual as of October 23, 2026 at 09:49 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:49 UTC.

From Medpace Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-10)

Key Strengths & Strategy (as disclosed to the SEC)

• Biometrics and Data Sciences: We provide high-quality data collected during clinical trials that supports regulatory submissions, including NDAs or Biologics License Application for approval by the FDA, or a similar marketing authorization application for approval by non-U.S. regulatory agencies.
• Department of Health and Human Services has promulgated rules under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and their implementing regulations, including the Privacy and Security Rules, or collectively, HIPAA, that govern the use, handling and disclosure of personally identifiable medical information.
• Working in a Good Laboratory Practice compliant setting following FDA and European Medicines Agency, or EMA, guidelines, the Bioanalytical Laboratory delivers method transfer, development, validation, sample analysis and metabolite screening and identification of pre-clinical and clinical biological samples with expertise in developing proprietary, highly scientific, esoteric and sensitive tests for small and large molecules.
• Our CTMs use ClinTrak, our proprietary information management system for clinical trials, which is integrated with our standard operating procedures (SOPs), allowing the CTMs to access real-time study metrics.

Legal & Regulatory Risks (Item 1A, quoted)

• Laws and regulations regarding the protection of personal data could result in increased risks of liability or increased cost to us or could limit our service offerings.
• Our business could be harmed from the loss or suspension of a license or imposition of a fine or penalties under, or future changes in, or interpretations of, the law or regulations of the Clinical Laboratory Improvement Act of 1967, and the Clinical Laboratory Improvement Amendments of 1988 (CLIA), or those of other national, state or local agencies in the U.S. and other countries where we operate laboratories.
• We may be affected by healthcare reform and potential additional regulatory reforms, which may adversely impact the biopharmaceutical industry or otherwise reduce the need for our services or negatively impact our profitability.
• The biopharmaceutical industry has a history of patent and other intellectual property litigation, and we might be involved in costly intellectual property lawsuits.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:49 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt